This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Auxology and response to growth hormone treatment of patients with intrauterine growth retardation or Silver‐Russell syndrome: analysis of data from the Kabi Pharmacia International Growth Study
Using the data base from the Kabi Pharmacia International Growth Study , 105 patients with intrauterine growth retardation ( IUGR ) ( 82 males , 23 females ) and 45 with Silver‐Russell syndrome ( SRS ) ( 32 males , 13 females ) with persistent postnatal growth failure were studied . Patients with IUGR had a birth length and birth weight more than 2 SD below the mean for gestational age . Their height deficit at the start of GH treatment was ‐3.0 SDS at a median chronological age of 8.7 years and a median bone age of 7.0 years . Mean paternal and maternal heights were 166 and 153 cm , respectively . The median dose  of GH  was 0.5 IU/kg/week , given at a median frequency of five injections/week . The median height SDS for chronological age after 1 , 2 and 3 years of GH treatment were ‐2.5 , ‐2.1 and ‐1.9 , respectively . In the 45 patients with SRS , median chronological age and median bone age at the start of treatment were 6.7 and 3.2 years , respectively , and mean paternal and maternal heights were 167.5 and 160 cm , respectively . The median dose of GH was 0.7 IU/kg/week , given at a median frequency of six injections/week . The median height SDS for chronological age at the start of treatment and after 1 , 2 and 3 years were ‐3.5 , ‐2.9 , ‐2.8 and ‐2.2 , respectively . Although the criteria used by physicians when diagnosing SRS were not controlled or verified in this study , it appears that patients with SRS can be differentiated from those with IUGR with persistent growth failure by their reduced bone age for chronological age at the start of treatment , and by the fact that patients with SRS tended to be born to parents of normal height  . GH treatment in both groups induced catch‐up growth , though long‐term follow‐up studies will be required to assess the effects of treatment on final height
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .